FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014031524910/23/14 new patent  Inducible eukaryotic expression system
22014028987609/25/14Mice that make heavy chain antibodies
32014027164209/18/14Il-33 antagonists and uses thereof
42014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
52014027165809/18/14Anti-il-33 antibodies and uses thereof
62014027168109/18/14High affinity human antibodies to human il-4 receptor
72014027309509/18/14Serum-free cell culture medium
82014027548909/18/14Apelin fusion proteins and uses thereof
92014028315809/18/14Rodents with conditional acvr1 mutant alleles
102014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
112014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
122014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
132014025599509/11/14High affinity antibodies to human il-6 receptor
142014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
152014024350408/28/14Antibodies comprising chimeric constant domains
162014024546608/28/14Humanized t cell co-receptor mice
172014024546708/28/14Genetically modified major histocompatibility complex mice
182014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
192014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
202014021377307/31/14Adam6 mice
212014019655007/17/14Systems and devices for sample handling
222014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
232014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
242014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
252014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
262014017887906/26/14Compositions and methods for modifying cells
272014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
282014015470106/05/14Humanized fc gamma r mice
292014015568906/05/14Methods of modifying genes in eukaryotic cells
302014015744506/05/14Low affinity fcgr deficient mice
312014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
322014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
332014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
342014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
352014013471905/15/14Recombinant cell surface capture proteins
362014013727505/15/14Hybrid light chain mice
372014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
382014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
392014013471905/15/14Recombinant cell surface capture proteins
402014013727505/15/14Hybrid light chain mice
412014013019305/08/14Mice that make vl binding proteins
422014013019405/08/14Mice that make vl binding proteins
432014013019305/08/14Mice that make vl binding proteins
442014013019405/08/14Mice that make vl binding proteins
452014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
462014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
472014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
482014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
492014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
502014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
512014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
522014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
532014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
542014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
552014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
562014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
572014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
582014007297903/13/14Isolating cells expressing secreted proteins
592014007298003/13/14Isolating cells expressing secreted proteins
602014007301003/13/14Methods of modifying eukaryotic cells
612014007558603/13/14Parental cell lines for making cassette-free f1 progeny
622014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
632014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
642014007297903/13/14Isolating cells expressing secreted proteins
652014007298003/13/14Isolating cells expressing secreted proteins
662014007301003/13/14Methods of modifying eukaryotic cells
672014007558603/13/14Parental cell lines for making cassette-free f1 progeny
682014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
692014005690702/27/14Anti-asic1 antibodies and uses thereof
702014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
712014004106802/06/14Methods of modifying eukaryotic cells
722014003333601/30/14Methods of modifying eukaryotic cells
732014003333701/30/14Methods of modifying eukaryotic cells
742014002363701/23/14Methods of modifying eukaryotic cells
752014001722801/16/14Humanized light chain mice
762014001722901/16/14Methods of modifying eukaryotic cells
772014001723801/16/14Methods of modifying eukaryotic cells
782014001769501/16/14Isolating cells expressing secreted proteins
792014001778101/16/14Methods of modifying eukaryotic cells
802014001778201/16/14Methods for modifying eukaryotic cells
812014001852201/16/14Methods of modifying eukaryotic cells
822014002012401/16/14Methods of modifying eukaryotic cells
832014002012501/16/14Methods of modifying eukaryotic cells
842014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
852014001345701/09/14Methods of modifying eukaryotic cells
862013034453812/26/13Human antibodies to the glucagon receptor
872013034010412/19/13Humanized il-7 rodents
882013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
892013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
902013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
912013032326112/05/13Purified antibody composition
922013032378812/05/13Production cell line enhancers
932013032379012/05/13Human lambda light chain mice
942013032379112/05/13Restricted immunoglobulin heavy chain mice
952013032664712/05/13Human lambda light chain mice
962013030967011/21/13Nuclease-mediated targeting with large targeting vectors
972013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
982013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
992013029509711/07/13Human antibodies to fel d1 and methods of use thereof
1002013028075810/24/13Fusion polypeptides capable of activating receptors
1012013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1022013026657410/10/13Human antibodies to human angiopoietin-like protein 4
1032013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
1042013025988110/03/13Fusion polypeptides capable of activating receptors
1052013026105610/03/13Vegf antagonist formulations
1062013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1072013025491109/26/13Adam6 mice
1082013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1092013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1102013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1112013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1122013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1132013023053109/05/13Human antibodies to clostridium difficile toxins
1142013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1152013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1162013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1172013020949208/15/13Anti-tie2 antibodies and uses thereof
1182013021013708/15/13Methods of modifying eukaryotic cells
1192013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1202013020949208/15/13Anti-tie2 antibodies and uses thereof
1212013021013708/15/13Methods of modifying eukaryotic cells
1222013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1232013019587808/01/13Anti-asic1 antibodies and uses thereof
1242013019887908/01/13Humanized universal light chain mice
1252013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1262013019587808/01/13Anti-asic1 antibodies and uses thereof
1272013019887908/01/13Humanized universal light chain mice
1282013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1292013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1302013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1312013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1322013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1332013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1342013018581907/18/13Genetically modified major histocompatibility complex animals
1352013018582007/18/13Genetically modified major histocompatibility complex animals
1362013018582107/18/13Common light chain mouse
1372013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1382013018581907/18/13Genetically modified major histocompatibility complex animals
1392013018582007/18/13Genetically modified major histocompatibility complex animals
1402013018582107/18/13Common light chain mouse
1412013017114907/04/13Anti-angptl3 antibodies and uses thereof
1422013017114907/04/13Anti-angptl3 antibodies and uses thereof
1432013016478606/27/13Fucosylation-deficient cells
1442013016478606/27/13Fucosylation-deficient cells
1452013015731306/20/13High affinity antibodies to human il-6 receptor
1462013016015306/20/13Humanized light chain mice
1472013015731306/20/13High affinity antibodies to human il-6 receptor
1482013016015306/20/13Humanized light chain mice
1492013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1502013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1512013013710105/30/13Methods of modifying eukaryotic cells
1522013013710105/30/13Methods of modifying eukaryotic cells
1532013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1542013012983005/23/13Polymer protein microparticles
1552013013037205/23/13Enhanced expression and stability regions
1562013013038805/23/13Methods of modifying eurakyotic cells
1572013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1582013012983005/23/13Polymer protein microparticles
1592013013037205/23/13Enhanced expression and stability regions
1602013013038805/23/13Methods of modifying eurakyotic cells
1612013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1622013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1632013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1642013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1652013011787305/09/13Humanized il-6 and il-6 receptor
1662013011787305/09/13Humanized il-6 and il-6 receptor
1672013010905305/02/13Genetically modified t cell receptor mice
1682013011161605/02/13Genetically modified major histocompatibility complex mice
1692013011161705/02/13Genetically modified major histocompatibility complex mice
1702013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1712013009628704/18/13Restricted immunoglobulin heavy chain mice
1722013008429704/04/13Anti-erbb3 antibodies and uses thereof
1732013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1742013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1752013007867503/28/13High affinity human antibodies to human il-4 receptor
1762013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1772013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1782013003490202/07/13Fusion polypeptides capable of activating receptors
1792013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1802012032210812/20/12Adam6 mice
1812012032349712/20/12Non-hypergeometric overlap probability
1822012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1832012026035710/11/12Low affinity fcgr deficient mice
1842012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1852012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1862012019230007/26/12Common light chain mouse
1872012017868307/12/12Vegf antagonist formulations
1882012016468806/28/12High affinity human antibodies to human nerve growth factor
1892012013501005/31/12High affinity human antibodies to human il-4 receptor
1902012012867905/24/12Human antibodies to the glucagon receptor
1912012011464505/10/12Use of il-1 antagonists to treat pseudogout
1922012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1932012011466505/10/12Human antibodies to human rankl
1942012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1952012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1962012010103504/26/12Vegf antagonist formulations
1972012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1982012009657204/19/12Mice that make vl binding proteins
1992012008792904/12/12Vegf antagonist formulations for intravitreal administration
2002012008300004/05/12Neuropeptide release assay for sodium channels
2012012007679003/29/12Anti-cd48 antibodies and uses thereof
2022012007086103/22/12Human lambda light chain mice
2032012007300403/22/12Hybrid light chain mice
2042012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
2052012005207203/01/12High affinity human antibodies to human il-4 receptor
2062012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
2072012002140901/26/12Common light chain mouse
2082012001496801/19/12Stabilized formulations containing anti-ngf antibodies
2092012000369701/05/12High affinity antibodies to human il-6 receptor
2102011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
2112011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2122011030796612/15/11Mice expressing human voltage-gated sodium channels
2132011030796812/15/11Production of fertile xy animals from xy es cells
2142011029363012/01/11Antibodies to human gdf8
2152011028337611/17/11Methods of modifying eukaryotic cells
2162011026918711/03/11High affinity human antibodies to human il-18 receptor
2172011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2182011025655610/20/11Humanized fcgr mice
2192011025658710/20/11High affinity human antibodies to human nerve growth factor
2202011025760110/20/11Vegf antagonist formulations for intravitreal administration
2212011025871010/20/11Methods of modifying eukaryotic cells
2222011019545408/11/11Common light chain mouse
2232011018917608/04/11Methods of treating diseases with dll4 antagonists
2242011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2252011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2262011016565007/07/11Fusion polypeptides capable of activating receptors
2272011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2282011015090506/23/11Human antibodies to human delta like ligand 4
2292011015451206/23/11Humanized fc gamma r mice
2302011014593706/16/11Mice that make heavy chain antibodies
2312011010479905/05/11Multifunctional alleles
2322011008168104/07/11Human antibodies to human cd20 and method of using thereof
2332011006590203/17/11High affinity human antibodies to pcsk9
2342011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2352011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2362011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2372011002728602/03/11High affinity human antibodies to human angiopoietin-2
2382011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2392011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2402011000837401/13/11Use of il-1 antagonists to treat gout
2412010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2422010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2432010031662712/16/10Human antibodies to human il-6 receptor
2442010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2452010030443612/02/10Fucosylation-deficient cells
2462010029110711/18/10High affinity human antibodies to human il-4 receptor
2472010029162611/18/10Enhanced expression and stability regions
2482010027993311/04/10Vegf antagonist formulations
2492010023380309/16/10Fusion polypeptides capable of activating receptors


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo